Citalopram treatment of major depressive disorder in Hispanic HIV and AIDS patients: a prospective study.
Fourteen Hispanic and six non-Hispanic outpatients with HIV-spectrum illness and major depressive disorder were enrolled in a 6-week, open-label, flexible-dose study of citalopram (dose range=10-40 mg/day). The depressive symptoms of 50% of the 14 patients who completed the study responded to citalopram (mean dose=34 mg/day). The treatment response rate, effective citalopram dose, total number of reported adverse events, and attrition rate did not differ between the ethnic groups. Two patients discontinued because of adverse events (rash, nausea), and four patients discontinued because of noncompliance with the protocol. The findings suggest that citalopram is an effective and well-tolerated antidepressant for Hispanic and non-Hispanic HIV-infected patients.
Currier
M Beatriz
MB
Department of Psychiatry and Behavioral Sciences, Division of Consultation Psychiatry, University of Miami School of Medicine, Florida 33136, USA. bcurrier@med.miami.edu
Molina
German
G
Kato
Martha
M
D000163:Acquired Immunodeficiency Syndrome / Q000208:ethnology* / Q000523:psychology*; D000293:Adolescent; D000328:Adult; D000368:Aged; D015283:Citalopram / Q000008:administration & dosage / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000208:ethnology / Q000209:etiology; D004334:Drug Administration Schedule; D005260:Female; D015658:HIV Infections / Q000208:ethnology* / Q000523:psychology*; D006630:Hispanic or Latino / Q000523:psychology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*
D015283:Citalopram; D017367:Selective Serotonin Reuptake Inhibitors